What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
Lawrence, Nicola J., Martin, Andrew, Davis, Ian D., Troon, Simon, Sengupta, Shomik, Hovey, Elizabeth, Coskinas, Xanthi, Kaplan, Richard, Smith, Benjamin, Ritchie, Alastair, Meade, Angela, Eisen, Tim,Volume:
2
Language:
english
Journal:
Kidney Cancer
DOI:
10.3233/kca-180038
Date:
August, 2018
File:
PDF, 424 KB
english, 2018